Who Needs Monitoring for Ozempic-Related Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Analysis

If you take Ozempic and have noticed persistent nausea, bloating, or abdominal pain, you may wonder about your risk for gastroparesis. This condition, which slows stomach emptying, has been linked to GLP-1 receptor agonists like Ozempic. Building on decades of research into drug-induced gastrointestinal disorders, this page reviews published evidence to clarify who may need closer monitoring and what symptoms to watch for.

The Medical Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. In recent years, a growing number of patients have reported severe gastrointestinal complications, including gastroparesis, after using this medication. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of a mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation can range from mild discomfort to debilitating episodes that require hospitalization. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, and it is essential to rule out other causes like diabetes itself, which can also cause gastroparesis. However, the temporal relationship between Ozempic initiation and the onset of these symptoms has raised concerns about a drug-induced mechanism. The pharmacology of Ozempic provides a plausible mechanistic pathway linking the drug to gastroparesis. GLP-1 receptor agonists like semaglutide slow gastric emptying as part of their therapeutic effect on postprandial glucose control. This delay in gastric motility is a known pharmacodynamic action, but in some individuals, it may become pathological, leading to gastroparesis. The drug's labeling acknowledges a high incidence of gastrointestinal adverse reactions. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which aligns with the potential for more severe motility disorders like gastroparesis.

Adequacy of Warnings and Risk Context

Beyond the common adverse reactions, the labeling also lists less frequent but clinically significant gastrointestinal events. In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5% were associated with Ozempic (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the constellation of symptoms—particularly dyspepsia, GERD, and nausea—can overlap with gastroparesis. The mechanistic link is further supported by the known effect of GLP-1 agonists on gastric motility, which can lead to delayed emptying and, in susceptible patients, full-blown gastroparesis. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central issue. The current labeling does not specifically mention gastroparesis as a potential adverse reaction, despite the drug's known effect on gastric emptying. The warnings section focuses on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may leave patients and healthcare providers unaware of the risk for a condition that can cause significant morbidity. For affected patients, settlement-related considerations hinge on whether the manufacturer provided adequate warnings and whether the harm was foreseeable. The timeline between exposure and documented harm is critical: patients typically develop symptoms during dose escalation or after several months of use, and the diagnosis of gastroparesis may be delayed due to the nonspecific nature of early symptoms. This delay can complicate legal claims, as the statute of limitations in Florida for personal injury actions generally runs from the date the injury is discovered or should have been discovered.

Statute of Limitations for Ozempic Gastroparesis Claims in Florida

For Ozempic-related gastroparesis, the clock may start when a patient receives a formal diagnosis or when symptoms become severe enough to prompt medical investigation. In Florida, the statute of limitations for product liability and personal injury claims is typically four years from the date of injury or discovery. However, for claims involving latent injuries, the 'discovery rule' may apply, extending the deadline. Patients who used Ozempic and later developed gastroparesis should consult with a legal professional to determine their specific timeline. Settlement considerations also include the strength of the evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the adequacy of the drug's labeling. Given the high incidence of gastrointestinal adverse reactions in clinical trials and the known pharmacological effect on gastric emptying, there is a plausible basis for claims that the manufacturer failed to warn about the risk of gastroparesis. Patients should gather medical records documenting the onset of symptoms, the timing of Ozempic use, and any diagnostic tests confirming gastroparesis. The risk narrative underscores the importance of timely legal action, as delays can jeopardize a claim. In summary, the evidence from clinical trials and pharmacological data supports a mechanistic link between Ozempic and gastroparesis, though the condition is not explicitly listed in the drug's warnings. Patients in Florida who have suffered this harm should be aware of the statute of limitations and the need for prompt legal evaluation. The adequacy of warnings remains a key risk anchor, and settlement outcomes will depend on individual circumstances, including the timeline of exposure and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for product liability and personal injury claims is generally four years from the date of injury or discovery. For latent injuries like gastroparesis, the discovery rule may apply, meaning the clock starts when the injury is discovered or should have been discovered. It is crucial to consult with a legal professional to determine your specific timeline.

Is gastroparesis listed as a side effect of Ozempic?

Gastroparesis is not explicitly listed in the current Ozempic labeling as a potential adverse reaction. However, the drug's known effect on slowing gastric emptying and the high incidence of gastrointestinal adverse reactions in clinical trials suggest a plausible link. The labeling does list symptoms like dyspepsia and GERD that can overlap with gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.